Coloplast A/S (OTCMKTS:CLPBY) Trading Down 2.3% – Here’s What Happened

Posted by Hanz Christensen on Dec 14th, 2024

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) shares traded down 2.3% on Thursday . The stock traded as low as $11.49 and last traded at $11.49. 216,857 shares changed hands during trading, an increase of 70% from the average session volume of 127,904 shares. The stock had previously closed at $11.76.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CLPBY shares. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a report on Monday, November 18th. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday.

Check Out Our Latest Stock Analysis on CLPBY

Coloplast A/S Stock Performance

The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.56 and a current ratio of 1.02. The company has a 50 day moving average price of $12.71 and a 200-day moving average price of $12.85.

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. The business had revenue of $1.02 billion for the quarter. As a group, equities analysts anticipate that Coloplast A/S will post 0.37 EPS for the current year.

Coloplast A/S Increases Dividend

The company also recently declared a dividend, which will be paid on Friday, December 20th. Investors of record on Monday, December 9th will be given a dividend of $0.2435 per share. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s payout ratio is currently 96.97%.

About Coloplast A/S

(Get Free Report)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.